Pembrolizumab-Induced Isolated Adrenocorticotropic Hormone (ACTH) Deficiency

Document Type

Article

Publication Date

1-1-2024

Publication Title

Cureus

Abstract

Pembrolizumab is a programmed death 1 receptor (PD-1) inhibitor. It is used as immunotherapy in various cancers, including metastatic melanoma, non-small cell lung cancer, and, notably, high-risk triple-negative breast cancer. We discuss a case of a 44-year-old female with a past medical history of triple-negative breast cancer who presented with a chief complaint of poor oral intake and fatigue after her fourth cycle of pembrolizumab therapy. The patient was diagnosed with pembrolizumab-induced isolated secondary adrenal insufficiency (AI) and was treated with corticosteroids with improvement in her symptoms. Secondary AI due to pembrolizumab use is a rare yet potentially life-threatening complication. If initial serum cortisol is borderline low, as observed in our patient, repeated testing within shorter intervals should be considered to optimize patient outcomes.

PubMed ID

38352096

Volume

16

Issue

1

First Page

52235

Last Page

52235

Find It @ Sladen

Share

COinS